Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:04:30·⟳ 抓取 19:04:51 +21s·⚡ 决策 10-21 19:07:55 +3m04s·6.2 天前
INmune Bio与Uniphar签订Ebstrocel国际分销主服务协议，布局欧洲/MENA指定患者用药通道
本条为同一事件的镜像转载（Investing.com AI改写稿），原始GlobeNewswire公司通稿已于2026-10-21 11:05 UTC被本臂处理并判不做；逐条比对事实完全一致，无金额修正、无新国家落地SOW、无监管进展等新增信息，属重复消息。
📄 原文Investing.com↗ 原文
INmune Bio partners with Uniphar for Ebstrocel distribution
BOCA RATON, Fla. - INmune Bio Inc. (NASDAQ:INMB) announced today that it has entered into a Master Services Agreement w…
不做 INmune Bio Inc.（INMB.US）
同一MSA催化已由GlobeNewswire首发并在约3分钟前被判不做，本条Investing.com镜像稿无任何新增事实（无金额、无保底、无新国家SOW、无监管进展）；协议仅为named-patient框架、产品未获批，微盘股流动性差，无正期望，重复消息不重复交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
INmune Bio与Uniphar的Ebstrocel国际分销MSA是同一事件的重复报道，无新增事实；且该协议仅为无金额、无保底、逐国SOW才落地的指定患者用药框架，产品尚未获批，缺乏可量化近期收入，微盘股流动性差，不具正期望。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 low · price-in 风险 medium ↗
主要风险
- Ebstrocel尚未获任何监管机构批准，MHRA/EMA申请分别在2026/2027年，存在临床或审批失败风险；MSA无金额、无保底收入，商业化兑现高度不确定。
先例如何影响了这次决策
对本次决策的影响:重复消息早停，未再检索先例；前次同一事件决策已覆盖判断。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,789 ms
{"result": "search_processed_events:agent query=`inmb ebstrocel named-patient access europe mena | inmune bio rdeb stromal cell therapy uniphar durbin partnership | inmune bio uniphar ebstrocel distribution master services agreem`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.9/72 小时、22126 条本臂决策(完整)，返回 1 条候选。\n• 10-2
原文全文
展开原文 · 2,153 字
BOCA RATON, Fla. - INmune Bio Inc. (NASDAQ:INMB) announced today that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited to establish a framework for international access, distribution and commercialization of Ebstrocel, the company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa.
The company initially plans to pursue named-patient access in selected European countries and in the Middle East and North Africa, subject to applicable law and country-specific statements of work, according to a press release statement. The relationship may expand across Europe and other territories by mutual agreement.
Named-patient access, where permitted by local law, may allow physicians to request Ebstrocel for individual eligible patients before local marketing approval or broad commercial availability.
Under the framework, Uniphar may support regulatory feasibility assessments, market access, product storage and distribution, healthcare-provider and treatment-site onboarding, order-to-cash services, medical information, pharmacovigilance support and end-to-end shipment tracking, depending on services agreed in individual statements of work.
"This agreement marks an important step in moving Ebstrocel from clinical development toward commercialization," said David Moss, Chief Executive Officer of INmune Bio.
Ruth Rostron, Head of Expanded Access at Uniphar, said the company is pleased to partner with INmune Bio as it prepares Ebstrocel for international commercialization.
Ebstrocel is an investigational, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy being developed for the treatment of RDEB. The therapy has not been approved by the FDA, MHRA, EMA or any other regulatory authority.
INmune Bio plans to file a Marketing Authorization Application with the UK MHRA in 2026 and the EU EMA in 2027.
Uniphar operates across 160 countries with a team of over 3,600 employees and has partnerships with more than 200 multinational clients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The company initially plans to pursue named-patient access in selected European countries and in the Middle East and North Africa, subject to applicable law and country-specific statements of work, according to a press release statement. The relationship may expand across Europe and other territories by mutual agreement.
Named-patient access, where permitted by local law, may allow physicians to request Ebstrocel for individual eligible patients before local marketing approval or broad commercial availability.
Under the framework, Uniphar may support regulatory feasibility assessments, market access, product storage and distribution, healthcare-provider and treatment-site onboarding, order-to-cash services, medical information, pharmacovigilance support and end-to-end shipment tracking, depending on services agreed in individual statements of work.
"This agreement marks an important step in moving Ebstrocel from clinical development toward commercialization," said David Moss, Chief Executive Officer of INmune Bio.
Ruth Rostron, Head of Expanded Access at Uniphar, said the company is pleased to partner with INmune Bio as it prepares Ebstrocel for international commercialization.
Ebstrocel is an investigational, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy being developed for the treatment of RDEB. The therapy has not been approved by the FDA, MHRA, EMA or any other regulatory authority.
INmune Bio plans to file a Marketing Authorization Application with the UK MHRA in 2026 and the EU EMA in 2027.
Uniphar operates across 160 countries with a team of over 3,600 employees and has partnerships with more than 200 multinational clients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
b3d334ead2· 2026-10-21 19:07 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前